{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"144"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"320"}],"units":"Participants"}],"description":"Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame.","groups":[{"description":"Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG000","title":"Treatment A"},{"description":"Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses)\n\nThen\n\nNivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG001","title":"Treatment B"},{"description":"Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle","id":"OG002","title":"Treatment C"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"From first to dose to 100 days following last dose (Up to 32 months)","title":"Number of Participants Experiencing Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}